Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Robert Cohen who wrote (15272)	2/18/1998 4:54:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Robert, LLY actually got the Biotech sector started in SD when they bought out Hybritech for $1/2 Billion in 1985?. If they follow a similar approach, a buyout wouldn't happen for a few years and it could be much higher than LGND's current or recent price. I think that long term investors would be better off without a buyout, but LGND's pipeline has to be extremely enticing for the big boys with products going off patent. LLY's deal with LGND was quite large and comprehensive and I think that they can develop blockbusters without a buyout. However, LGND does have about 100 targets, and long term, a buyout might be cheaper. As far as a price is concerned, your guess is as good as mine and probably far better than the $15 price posted a couple of weeks ago by one of the more prolific posters. I suspect that the $15 was a joke. I know I would place many of the posts and predictions in that category, but who knows. Some still think that $18 for LGND is high.